the aid library

Filter

4232

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171 countries across all six WHO Regions and was rapidly re ... more

Nigeria: reducing the indirect causes of maternal morbidity and mortality: the RICOM3 Project

World Health Organisation (WHO) (2023) C_WHO

Nigeria reported its first case of COVID-19 at the end of February 2020 and subsequently experienced four waves, with peaks in June 2020 and January, August and December 2021. The COVID-19 pandemic severely impacted the economy of Nigeria and caused disruption of health services nationwide. During ... more

Good practice statement on the use of variant-containing COVID-19 vaccines

World Health Organization WHO (2022) C_WHO

Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage. This guidance should be considered along with the broader COVID- ... more

La participation des enfants dans l'aprentissage et action pour la prévention et le controle de la diarrhée

Children for Health (2020) CC

Le document fournit des messages éducatifs et des conseils pratiques pour prévenir et gérer la diarrhée, en particulier chez les enfants. Il met l'accent sur les pratiques d'hygiène telles que le lavage des mains adéquat, l'utilisation de latrines et la manipulation sûre des aliments. Il soul ... more

Analyses en laboratoire pour la détection du virus de la variole du singe (orthopoxvirose simienne)

World Health Organisation (WHO) (2022) C_WHO

L’orthopoxvirus simien ou virus de la variole du singe (MPXV), est un virus à ADN double brin qui appartient au genre Orthopoxvirus de la famille des Poxviridés. Les poxvirus causent des maladies chez l’espèce humaine et beaucoup d’autres animaux ; l’infection se manifeste généralement ... more

Infection Prevention and Control (IPC) Standard Operating Procedure (SOP) for Training/Meetings in the context of COVID-19
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) CC

1.0 PURPOSE To define the procedure for the conduct of in-person meetings in both healthcare and community settings in response to COVID-19 and with respect to Public Health and Social Measures (PHSMs) to reduce the risk of disease transmission. A general risk assessment must be conducted to inform ... more

Haiti: Hurricane Matthew - Situation Report No. 22 (16 November 2016)

UN Office for the Coordination of Humanitarian Affairs (2016) C1

Main Points The delivery of humanitarian assistance is expected to slow down significantly over the next seven to ten days in anticipation of the electoral process and limited availability of transport and security assets. The percentage of extremely food-insecure people who have recei ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Identifying Early Adopters of COVID-19 Vaccines in Latin America

Arrieta, A.; A. García-Prado, J.P. Sarmiento, et al. Florida International University (2021) CC

COVID-19 vaccine hesitancy is currently one of the main obstacles to worldwide herd immunity and socioeconomic recovery. Because vaccine coverage can vary between and within countries, it is important to identify sources of variation so that policies can be tailored to different population groups. ... more

COLERA: INFORMAÇA O PARA PROMOTORES DE SAUDE ou ACTIVISTAS

World Health Organisation (WHO) (2019) C2

The PDF "COLERA: Informação para Promotores de Saúde" provides essential guidance for health promoters and activists on cholera. It explains that cholera is characterized by severe watery diarrhea, often resembling rice water, and sometimes vomiting. If not treated promptly, it can lead to death ... more

Monthly Regional Cholera Bulletin

World Health Organisation (WHO) (2024) C_WHO

The World Health Organization (WHO) African Region website provides comprehensive information on cholera outbreaks across the continent. In 2024, 14 countries, including the Democratic Republic of the Congo, Ethiopia, and Nigeria, experienced significant outbreaks, with these three nations categoriz ... more

Ethiopia - Multi-Sectorial Cholera Elimination Plan 2022 - 2028

Government of Ethiopia (2023) C2

The Ethiopia Multi-Sectorial Cholera Elimination Plan (2022-2028) outlines a national strategy to eliminate cholera in Ethiopia by 2028. The plan follows the Global Roadmap to End Cholera by 2030 and is based on six key pillars: Leadership & Coordination, Water, Sanitation & Hygiene (WASH), Surveill ... more

COVID-19: Strategic preparedness and response plan for WHO African Region 1 February 2021-31 January 2022 (Update of 16 April 2021)

World Health Organization WHO, Regional Office of Africa; UNICEF (2021) C_WHO

The 2021 COVID-19 Strategic Preparedness and Response Plan (SPRP) for AFR serves as a regional guide for a holistic public health response to COVID‑19 at regional, national and sub-national levels. The 2021 SPRP: 1. Builds upon the lessons learnt from the implementation of the 2020 SPRP and outl ... more

COVID-19 vaccine tracker and landscape
recommended

World Health Organization WHO (2022) C_WHO

The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline. The COVID-19 vaccine tracker: Provides summary tables of COVID-19 vaccine candidates in both clinical and pre- ... more

Plan national de réponse à l’épidémie de choléra au Cameroun. Août–Octobre 2018

République du Cameroun, Ministère de la santé publique (2018) CC

The document presents Cameroon's National Response Plan for the 2018 cholera outbreak, covering August to October 2018. It highlights the epidemiological situation, with outbreaks reported in the North and Central regions and a total of 109 suspected cases and 9 deaths by July 2018. The plan outline ... more

Clinical management of COVID-19: living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

As of 12 December 2022, over 645 million people worldwide have been diagnosed with COVID-19, with over 6.6 million deaths (4). The Omicron variant, which emerged in late November 2021, and its subvariants, are now the dominant circulating viruses, contributing to the ongoing surge in several countr ... more

Rabies vaccines and immunoglobulins: WHO position

World Health Organization World Health Organization WHO (2017) C_WHO

The new WHO recommendations for rabies immunization supersede the 2010 WHO position on pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for rabies. These updated recommendations are based on new evidence and directed by public health needs that are cost-, dose- and time-sparing ... more

Maldives National Action Plan for Containment of Antimicrobial Resistance 2017-2022

Maldives Food and Drug Authority Ministry of Health (2017) C2

Maldives has made significant strides in the area of infectious disease prevention and control. This is exemplified by elimination of malaria from Maldives in 2015 and successes in TB control. In addition, Maldives is a front runner in infectious disease prevention through successful water, sanitati ... more

Syrian Arab Republic - Overview of humanitarian response from within Syria

OCHA (2020) C1

January - December 2019 First published April 2020 • Between January to December 2019, an estimated 8.58 million people were reached at least once with some form of humanitarian assistance, including over 91,000 people through three inter-agency convoys, two to Rukban and one to Menbij. On ... more

Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19, 2 July 2021

World Health Organization WHO (2021) C_WHO

Countries across the world are facing diverse epidemiological situations with varying response capacities and access to life saving tools. The World Health Organization (WHO) recommends that national authorities continue to apply a risk-based approach when implementing measures related to COVID-19 ... more